NCT04475016View on ClinicalTrials.gov

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

May 6, 2022

Study Completion Date

May 30, 2022

Conditions
Penile Cancer
Interventions
DRUG

Albumin-Bound Paclitaxel

260 mg/m² IV over 30 minutes on Day 1

DRUG

Ifosfamide

1200 mg/m² IV over 2 hours on Days 1-3

DRUG

Cisplatin

25 mg/m² IV over 2 hours on Days 1-3

DRUG

Nimotuzumab

400 mg IV on Day 1

DRUG

Triprilimab

240 mg IV on Day 1

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT04475016 - TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | Biotech Hunter | Biotech Hunter